Rubius reports $26.4M loss for Q3

PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an $11.9 million loss in the third quarter of 2017. The company, which specializes in allogenic cellular therapies for several diseases and across multiple therapeutic areas, has yet to have a product…
To read the full story, Subscribe or
Subscribe to PBN
- Advertisement -